A large study published in The Lancet has found that people with autoimmune diseases have an approximately 1.4–3.6-fold increased risk for developing cardiovascular disease relative to the general population.
Pioglitazone, a peroxisome proliferator activated receptor-γ agonist, is associated with improvements in vascular stiffness and various cardiometabolic parameters in patients with systemic lupus erythematosus, show study findings.
The overall burden of vascular plaque measured on ultrasound scans is significantly associated with future risk for cardiovascular disease events in people with systemic lupus erythematosus, study findings indicate.
Research suggests that using a daily hydroxychloroquine dose of 5 mg/kg or lower, as recommended by ophthalmology guidelines, is associated with an increased risk for systemic lupus erythematosus flares compared with higher doses.
Individuals with rheumatic conditions living in areas with the highest social and heat vulnerability are significantly more likely to experience recurrent hospitalizations than those living in the least vulnerable areas, research suggests.